Compounds That Could Delay Brain Diseases Identified

A "structure-based" approach to drug design has led to identification of compounds with the potential to delay or treat Alzheimer's disease, and possibly Parkinson's, Lou Gehrig's disease and other degenerative disorders. Structure-based drug design, in which the physical structure of a targeted protein is used to help identify compounds that will interact with it, has already been used to generate therapeutic agents for a number of infectious and metabolic diseases.  read more

Read the whole article on

More from